Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: HER-2 Gene Amplification|HER2-positive Gastric Cancer|HER2-positive Breast Cancer|HER-2 Protein Overexpression|Solid Tumor, Adult
Interventions: BIOLOGICAL: chimeric antigen receptor (CAR) T cell therapy
Sponsor: Bellicum Pharmaceuticals